Evidence map›Paper›PMID 40490670›Full record

ArticleEndocrine2025

Quality of life and treatment burden of children receiving daily growth hormone treatment in Greece.

Athanasios Christoforidis, Fotini-Eleni Karachaliou, Assimina Galli-Tsinopoulou, Dionisios Chrysis, Christina Kanaka-Gantenbein, Evangelia Baxevanidi, Ioannis Skiadas, Oresteia Zisimopoulou, Apostolia Poimenidou, Dimitrios Tsilakis and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Athanasios ChristoforidisFirst Department of Paediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Ippokratio General Hospital, Thessaloniki, Greece.
Fotini-Eleni KarachaliouThird Department of Paediatrics, Medical School, National and Kapodistrian University of Athens, University General Hospital "ATTIKON", Athens, Greece.
Assimina Galli-TsinopoulouSecond Department of Paediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece.
Dionisios ChrysisDivision of Paediatric Endocrinology, Department of Paediatrics, Medical School of Patras, University Hospital, Rio, Patras, Greece.
Christina Kanaka-GantenbeinDivision of Endocrinology, Diabetes and Metabolism, "Aghia Sophia" Children's Hospital Endo-ERN Center for Rare Paediatric Endocrine Disorders, Athens, Greece.
Evangelia BaxevanidiPfizer Hellas S.A., Athens, Greece. eva.baxevanidi@pfizer.com.
Ioannis SkiadasPfizer Hellas S.A., Athens, Greece.
Oresteia ZisimopoulouPfizer Hellas S.A., Athens, Greece.
Apostolia PoimenidouPfizer Hellas S.A., Athens, Greece.
Dimitrios TsilakisPfizer Hellas S.A., Athens, Greece.
Elpis-Athina VlachopapadopoulouDepartment of Endocrinology-Growth and Development, General Children's Hospital "Panagiotis & Aglaia Kyriakou", Athens, Greece.
GHEA Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to assess the paediatric growth hormone deficiency burden in Greek patients and their caregivers regarding the health-related quality of life (HRQoL), impact of recombinant human growth hormone (rhGH) treatment, and disease management.

methodIn this cross-sectional study, Quality of Life in Short Stature Youth (QoLISSY) and Life Interference for GHD (LIQ-GHD) questionnaires were administered to both patients with pGHD aged 4-17 years receiving rhGH for minimum 12 months and their caregivers.

resultsThis study included 250 patients and their caregivers. The mean ( ± SD) total QoLISSY scores were 80.93 (±14.63) and 76.32 (±17.68) reported by patients and caregivers, respectively. Patients ≥ 8 years scored higher in total and emotional domains compared to caregivers, whereas the treatment domain was lower in patients > 12 years versus caregivers. Ease of injection schedule, life interference, and willingness to continue LIQ-GHD domains mainly comprised treatment burden, with mean (±SD) scores of 19.88 (±22.02), 19.36 (±18.39) and 19.25 (±19.60), respectively. Treatment adherence in the overall population was satisfactory. Patients ≥ 8 years missed more injections than younger individuals.

conclusionA good HRQoL and a mild treatment burden were reported by Greek patients receiving daily rhGH and their caregivers; however, variability was observed within children's and caregivers' groups. Considering the decreased compliance during adolescence, emphasis should be given to consultations with patients and caregivers to identify issues and address them accordingly. Finally, there is a need to consider alternative treatment regimens which could improve adherence.

Indexed as

Cost of IllnessDwarfism, PituitaryHuman Growth HormoneQuality of LifeAdolescentCaregiversChildChild, PreschoolCross-Sectional StudiesFemaleGreeceHumansMaleRecombinant ProteinsSurveys and QuestionnairesHuman Growth HormoneRecombinant ProteinsChildrenGreeceGrowth hormone deficiencyGrowth hormone treatmentHealth-related quality of lifeTreatment burden

Identifiers

PMID40490670
PMCPMC12370556

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.